CURRICULUM VITAE 1. Personal information: First Name ...

1. Personal information:
CURRICULUM VITAE
First Name: Mohammad Hossein
Family Name: Alimohammadian
Birth Place: Iran, Ardabil Birth Date : 8 May 1946
Nationality: Iranian
Academic Rank: Professor
Address: Department of Immunology,
Pasteur Institute of Iran, Pasteur Avenue 69., Tehran, Iran.
Tel: (0098 21) 6696 88 57
Fax: (009821) 6646 51 32
E-mail mhalimohammadian@yahoo.com
2. EDUCATION:
Doctor of Pharmacy, School of Pharmacy, Tehran University, 1964-1970
Medical diagnostic laboratory specialist (MDLS), School of Medicine, Tehran
University, 1975-1980.
Post-doctorial short courses in advance immunology: a) WHO Sponsored Course in
Immunology and Molecular Biology Applied for Infectious Diseases, Institute of
Biochemistry, Lausanne University, Switzerland, September 13 - October 21, 1989;
b) a training and reseach course in practical immunology, Institue of Biochemistry,
Lausanne University, Switzerland, October 22 -December 9, 1989, c) a training course
in hybridoma technoloy, SDS-PAGE, Immunobloting, and ELISA, Dept. of Vaccine,
State Serum Institute, Copenhagen, December 11, 1989 - March 14, 1990, and d) a
training and research course in T cell proliferation assay, human T-cell cloning and
cytokine bioassay, Dept. of Clinical Microbiology, University of Copenhanen,
Denmark, September 2 - October 29, 1991.
Sabbatical Course in molecular biology and genetic: School of Biological Sciences,
University of Liverpool, Liverpool, UK, February 17, 2004, Feb 16, 2005.
3. Theses:
Parm D thesis: Analysis of amino acids in nutritional proteins by gas chromatography,
Pharmacy doctorate, Major supervisor: Dr. Farrahi, School of Pharmacy, Tehran
University, Tehran, 1969-1970.
MDLS thesis: Studies of the effect of levamisol on the immune responses of mice
infected with Leishmania. Major supervisor: Dr Farrokh Modabber, School of public
Health, Tehran University, Minor Supervisors: Dr E. Javadian, School of public
Health, Tehran University, Dr. E Beral, Medical Faculty, Tehran University, from
1978-1980.
4. Honors and Awards:
1

4.1. A research training grant awarded by UNDP/World Bank/ WHO, Special
Programme for Research and Training in Tropical Diseases (TDR) for 6 months in
Switzerland and Denmark, September 1989 - March 1990.
4.2. Kharazmi International Festival Award: awarded by President of Islamic Republic
of Iran. Organized by Iranian Scientific and Industrial Researchs Organization,
Ministry of Culture and High Education, February 1996.
4.3. Research third grade Medal, awarded by President of Islamic Republic of Iran,
October 2004.
5. Projects completed:
5.1. The effect of Naloxone on immunological responses of BALB/c mice infected with
Leishmania major (1387-1388).
5.2. Clinical trial for comparison of two Leishmania antigens of QuantiFERON with
leishmanin skin test on individuals with history of leishmaniasis in Iran (87-88).
5.3. Cloning, expression and immunologic evaluation of Leishmania infantum Nuclease
(P4) (1385-1388).
5.4. Polymorphism in cytokine genes in different clinical forms of cutaneous Leishmaniasis.
Pasteur Institute of Iran, 2006-2008.
5.2. Correlation of anaemia associated with Trypanosoma congolense infection in susceptible
and resistant mice strains via expression of IREG1 and IL-6 genes. School of Biological
Sciences, University of Liverpool, UK, 2004-2005.
5.3. Identification of Leishmania species and sub-species in endemic areas of
leishmaniasis by biochemical, immunological and molecular
methods.
Pasteur Institute of Iran, 2002- 2008.
5.4. Isolation and evaluation the immunogenicity of membrane proteins of L. major
amastigotes in peripheral mononuclear cells of healed leishmaniasis individuals,
Pasteur Institute of Iran, 2002-2008.
5.5. Collection, cataloging, characterization and storage of L. major isolates, TDR-
Pasteur Institute of Iran, Tehran, 1999-2002.
5.6. Study on immunogenicity of procyclic promastigotes and amastigotes of L. major in
human and mice model, Pasteur Institute of Iran, 1999-2001.
5.7. Identification of Leishmania major fraction responsible for DTH. Pasteur Institute,
Tehran, Iran, 1998-2001.
5.8. Evaluation of the immunogenicity of three doses of killed Leishmania major
vaccine in healthy volunteers, Center for Research and Training on Skin Diseases
& Leprosy, and Pasteur Institute of Iran, 1999-2001.
5.9. Study on adjuvanity effect of Leishmania major on the immune responses of mice
immunized with ovalbumin. Pasteur Institute, Tehran, Iran, 1998-2000.
5.10. Study on T cell phenotypes and cytokine profile in patients with cutaneous
leishmaniasis and recovered cases, in endemic areas of Kashan and Tehran.
Pasteur Institute, Tehran, Iran, 1996-1998.
5.11. Preparation and evaluation of soluble and phenol leishmanin. TDR-Pasteur
Institute, Tehran, Iran, 1995-1999.
5.12. Semi-industrial production of Leishmanin and its evaluation in endemic areas of
cutaneous leishmaniasis, Pasteur Institute of Iran, 1996-1997.
2

5.13. Preparation of killed Leishmania major vaccine for vaccine studies. TDR-Pasteur
Institute, Tehran, Iran, 1994-1996.
5.14. Preparation and evaluation of a standard soluble Leishmania major antigen in semiindustrial
scale, TDR- Pasteur Institute, Tehran, Iran, 1990-1994.
5.15. Preparation of skin test antigen from Leishmania major for use in human for
diagnostic and experimental purposes. TDR - Pasteur Institute, Tehran, Iran,
1987-1990.
Current project:
5.1’. Study on the role of regulatory T and Th-17 cells in symptomatic and
asymptomatic clinical forms of Leishmania major infection
5.2’. Cloning and expression of recombinant protein of hepcidin and its application
in treatment of susceptible mice to Leishmania major (88-90).
5.3’. Semi-industrial production of leishmanin from Leishmania major for skin
testing in order to use in leishmaniasis epidemiology and candidate
leishmaniasis vaccine studies (1387-1389).
6. Grants:
6.1 World Health Organization, TDR. Preparation and evaluation of standard leishmanin.
US $ 76, 520 for five different grants, 1987-2002.
6.2. World Health Organization, TDR. Preparation and evaluation of killed L. major
vaccine. $ 13, 000. from 1993-1994.
6.3. World Health Organization, TDR. Collection, cataloging, characterization and
storage of L. major isolates. $ 20,000, 1999-2002.
7. Theses directed:
7.1. Cloning and expression of fish ferroportin (IREG1) and study of its influence on
Major,
Anemia treatment of BALAB/c mic infected with Leishmania major. PhD,
Islamic Azad University, Tehran 2008- 2010.
7.2. Producing and analysis the effect of recombinant hepcidin on proliferation of
NS-1 cell line and J774 A.1 infected with Leishmania major. PhD, Major,
Isfahan
University of Medical science, Isfahan, 2008-2010.
7.3. Comparative studies of Th1 and Th2 cytokines mRNA by RT-PCR in mice
inoculated with different strains of Leishmania major. MS, Major, Islamic Azad
University, Tehran, 2007-2009.
7.4. Separation and characterization of glycoconjugate from Iran Leishmania major.
PhD, Minor, Institute of Biochemistry and Biophysics, University of Tehran,
2004-2006.
3

7.5. Cloning, expression and immunological evaluation of P4 protein of Leishmania
major. PhD, First Major, Pasteur Institute of Iran, Tehran, Iran, 2002-2005.
7.6. Characterization of different strains of Leishmania major in Iran and study on
immunogenicity and pathogenicity of various strains to select most immunogenic
strain for vaccine, PhD, Major, Pasteur Institute of Iran, Tehran, 2000-2003.
7.7. Preparation and characterization of monoclonal antibody against amastigote stage of
Leishmania major and studing it's role in immunotherapy of infected BALB/c
mice. PhD, First Major, Pasteur Institute of Iran, Tehran, Iran, 1998-2002.
7.8. Investigation on production of gamma interferon, interleukine-12 and
Interleukine-10 cytokines in response to different forms (procyclic, and axenic
amastigotes) of Leishmania major parasites, First Major, Tehran University of
Medical Sciences, Tehran, Iran, 1998-2001.
7.9. Investigation of cellular immunity in patients with cutaneous leishmaniasis and
recovered individuals. Second Major, School of public Health, Tehran University
of Medical Sciences, Tehran, 1997-2000.
7.10. Expression of glycoprotein 63 (Gp63) gene of Leishmania major in E. coli.
Second Major, Pasteur Institute of Iran, Tehran, Iran, 1998-1999
7.11. Purification of IgE from the serum of atopic patients, production of monoclonal
antibody for designing ELISA kit, Minor, University of Tarbiat Modarres, Tehran,
1997-1999.
7.12. Preparation and characterization of murine monoclonal antibodies against major
subsets of hepatitis B surface antigen, Major, Pasteur Institute of Iran, Tehran,
Iran, 1996-1999.
7.13 Biochemical analyses and evaluation of immunogenic fraction of Leishmania
major amastigotes. First Major, Pasteur Institute of Iran, Tehran, Iran, 1994-1996.
7.14. Immunological evaluation of Leishmania major antigenic fractions by
biochemical methods. Minor, University of Tarbiat Modarres, Tehran, 1994-1996.
Also another 16 theses of MS and MSc have been supervised.
8. Books:
Manual of Laboratory Immunology, Miller, LE, Ludke HR, Peacock JE, and Tomar RH.
Translated by Alimohammadian, MH and Mahmoodzadeh-Niknam, H, Publisher:
Negareh, from English to farsi, 1995.
9. Teaching:
Ph.D course in Advance Immunology, Pasteurr Institute of Iran 1999- present
- M.Sc course in Immunology of infectious diseases, Pasteurr Institute of Iran 1999-
present
-Advanced Immunology for PhD parasitology students, Iran University of Medical
Sciences, 2001-2003
- Immunology for PhD students of biotechnology, IBB, Tehran University , 2007
10. Articles:
4

Enzyme Research
1.
•
1. Rafiei A, Fatemi SMR, Jamili Sh, Ajdary S, Riazi-rad F, Memarnejadian A and
Alimohammadian MH (in press) Cloning, expression and characterization of zebra
fish ferroportin in Hek 293T cell line. Iranian J publ Health.
2. Yazdani Y, MM Sadegi H, Alimohammadian MH, Andalib A, Moazen F, Rezaei A.
(in press) Expresion of an innate immune element (mouse Hepcidin) in baclovirus
expression system and comparison of its function with synthetic human Hepcidin-
25. Iranian J of Parmaceutical Research.
3. Farajnia S, Rahbarnia L, Maleki zanjani B, Alimohammadian MH, Abdoli Sh, Beh-
Pajooh A, Saeedi NMontazer Saheb S. 2011) Molecular Cloning and characterization
of P4 Nuclease from Leishmania infantum. Enzyme Research, Epub 2011 Jun 28.
4. Ajdary S, Ghamilouie MM, Alimohammadian MH, Riazi-Rad F, Pakzad SR. (2011)
Toll-like receptor 4 polymorphisms predispose to cutaneous leishmaniasis.
Microbes and Infection, 13: 226-231.
5. Mahmoodzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M,
Alimohammadian MH, Parvizi P, Hatam GhR, Mohabali M, Khalaj V. (2011) The
problem of mixing up of Leishmania isolates in the Laboratory: suggesting of ITS1
gene sequencing for verification of species. Iranian J Parasitol, 6: 41-48.
6. Alimohammadian MH, Darabi H, Ajdary S, Khaze V, Torkabadi E. (2010)
Genotypically distinct strains of Leishmania major display diverse clinical and
immunological patterns in BALB/c mice. Infect Genet Evol.! 10: 969-75.
7. Mahmoodzadeh-Niknam H, Abrishami F, Doroudian M, Moradi M,
Alimohammadian MH, Parvizi P. (2010) Complete conservation of an
immunogenic gene (lcr1) in Leishmania infantum and Leishmania chagasi isolated
from Iran, Spain and Brazil. J Vector Borne Dis 47: 204-210.
7. Akhavan AA, Yagobi-Ershadi MR, Mirhendi H, Alimohammadian MH, Rassi Y,
..Khamesipour A. et al (2010). Molecular epizootiology of rodent leishmaniasis in a
hyperendemic area of Iran. Iranian J publ Health 39: 1-7.
8. Ajdary S, Ghamilouie MM, Alimohammadian MH, Hosseini M, Pakzad SR. (2010)
Lack of association of Toll-like receptor 2 Arg753Gln with cutaneous
leishmaniasis.Parasitol Int. 59: 466-68.
9. Akhavan AA, Mirhendi H, Khamesipour A, Alimohammadian MH, Rassi Y, Bates
P, Kamhawi S, Valenzuela JG, Arandian MH, Abdoli H, Jalali-Zand N, Jafari R,
Shareghi N, Ghanei M, Yaghoobi-Ershadi MR.(2010) Leishmania species:
Detection and identification by nested PCR assay from skin samples of rodent
reservoirs, Exp Parasitol. 126: 552-6.
10. Akhavan AA, Yaghoobi-Ershadi MR, Khamesipour A, Mirhendi H,
Alimohammadian MH, et als (2010) Dynamics of Leishmania infection rates in
Rhombomys opimus (Rodentia: Gerbillinae) population of an endemic focus of
zoonotic cutaneous leishmaniasis in Iran.Bull Soc Pathol Exot, 103(2):84-9.
11. Kavoosi G, Ardestani SK, Kariminia A, Alimohammadian MH.(2010) Leishmania
major lipophosphoglycan: discrepancy in Toll-like receptor signaling. Exp
Parasitol, 124(2):214-8.
12. Ajdary S, Riazi-rad F, Alimohammadian MH, Pakzad SR. Immune response to
Leishmania antigen in anthroponotic cutaneous leishmaniasis. Journal of Infection
2009, 59: 139-143.
5

13. Noyes HA, Alimohammadian MH, Agaba M, Brass A, Fuchs H, Gailus-Durner V,
Hulme H, Iraqi F, Kemp S, Rathkolb B, Wolf E, de Angelis MH, Roshandel D,
Naessens J. Mechanisms controlling anaemia in Trypanosoma congolense infected
mice. Plos One 2009, 4: 1-13.
14. Farajnia S, Darbani B, Babaei H, Alimohammadian MH, Mahboudi F, Gavgani AM.
Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of
visceral leishmaniasis in Iran. Parasitology 2008, 19:1-7.
15. Kavoosi G, Ardestani SK, Kariminia A, Zeinali M, Alimohammadian MH. Leishmania
major: Effects of proteophosphoglycan on reactive oxygen species, IL-12, IFNgamma
and IL-10 production in healthy individuals. Exp Parasitol. 2008!, 120: 62-66.
16. Alimohammadian MH, Darabi H, Malekzadeh Sh, Mahmoodzadeh-Niknam H, Ajdary S,
Khamesipour A, Bahonar A, Mofarrah A. Exposure to Leishmania major modulates the
proportion of CD4+ T cells without affecting cellular immune responses. Microbiology
and Immunology 2007, 51: 1003-1011.
17. Tashakori M, Kuhls K, Al-Jawabreh A, Mauricio I, Schonian G, Farajnia S, Alimohammadian MH. (2006)
Leishmania major: Genetic heterogenecity of Iranian isolates by single-strand conformation polymorphism
and sequence analysis of ribosomal DNA internal transcribed spacer. Acta Tropica 98: 52-58.
18. Khabiri AR, Bageri F, Alimohammadian MH, Assmar M, Nadaf SR. (2005) Leishmanin skin test in guinea
pig with a single purified protein of Leishmania major Exp Parasitol, 111: 239-243.
19. Farajnia S, Mahboodi F, Ajdari S, Reiner NE, Kariminia A, and Alimohammadian MH. (2005). Mononuclear
cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I
nuclease with a predominant Th1-like response. Clin Exp Immunol, 139: 498-505.
20. Farajnia S, Alimohammadian MH, Reiner NE, Karimi M, Ajdri S, Mahboudi F. (2004). Molecular
characterisation of a novel amastigote stage specific class I nuclease from Leishmania major. Int. J.
Parasitol., 34: 899-908.
21. Mirjalili A, Alimohammadian MH and Khabiri A. (2004). Improvement of Leishmania major Amastigote
ELISA test using various antigen-antibody dissociating agents and pepsin degestion. Arch. Razi Ins. 57: 33-
44.
22. Rezaeian A, Alimohammadian MH, Zeinali S. (2003). Microsatellie analysis of mouse TNF and Cypla2 loci
for polymorphism: detection and evaluation of genetic contamination. Scand. J. Lab. Anim.Sci., 30:143-149.
23. Mirjalili A, Alimohammadian MH, Madani R. (2003). Presence of immunoglo-bulins on the surface of lesiondrived
amastigotes of Leishmania major as a tool for isolation of amastigote stage from BALB/c mice.
Iranian Biomedical Journal, 7: 155-160.
24. Tashakori M, Ajdari S, Kariminia A, Mahboudi F and Alimohammadian MH. (2003) Chracterization of
Leishmania species and L. major strains in different endemic areas of cutaneous leishmaniasis in Iran.
Iranian Biomedical Journal, 7: 43-50.
25. Alimohammadian MH, Khamesipour A, Darabi H, Firooz AR, Malekzadeh S, Bahonar A, Dowlati Y,
Modabber F. (2002) The role of BCG in human immune responses induced by multiple injections of
autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21: 174-180.
26. Darabi H, Abolhasani M, Kariminia A, Alimohammadian MH (2002) Expansion of T cells in patients
infected with cutaneous leishmaniasis with and without glucantim therapy. The Brazilian Journal of
Infectious Diseases, 6: 258-262.
27. Alimohammadian MH, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, Ajdary S, and Kharasmi A.
(2002) Adjuvant effect of Leishmania major promastigotes on the immune response of mice to ovalbumin.
Iranian Biomedical Journal, 6: 123-128.
28. Khabiri AR, Abolhasani M, Aslani S, Darabi H, Bageri F, and Alimohammadian MH. (2001)
Compositional changes of PBL population in Patients with chronic hepatitis B virus infection. The
Brazilian Journal of Infectious Diseases, 5: 345-351.
29. Kariminia A, Darabi H, Keyhani A, and Almohammadian MH. (2001). Induction of Th1 cytokines by live
logarithmic promatigotes of L. major. Iranian Biomedical Journal, 5:15-20.
30. Malakaneh M, Rasaee MJ, Rahbanizadeh F, Madani R, Forozandeh MM, Khabiri AR, Alimohammadian MH
(2001) Chracterization of a monoclonal antibody against neopetrin using an enzyme-linked immunosorbent
assay with penicillinase as lable. Hybridoma 20: 117-121.
31. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, and Kharazmi A. (2000). Comparison of the
immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those
who have recovered from infection. Infection and immunity, 68: 1760-1764.
32. Kariminia A, Keyhani A, Asslanian S and Alimohammadian. (2000) Live logarithmic phase
promastigotes of Leishmania major induce high level of IFN- but lower level of IL-10 in whole blood
culture of healthy individuals. Acta Medica Iranica, 38: 168-173.
6

33. Majidi J, Zavaran H, Hassan ZM, Alimohammadian MH. (2000) Production of monoclonal antibody against
human immunoglobulin E. Iranian Journal of Allergy, Asthma and Immunology, 1:81-87.
34. Alimohammadian MH, Almasi H, Khabiri AR, Hatam GR, Karimi A, Mahboudi F, Tehrani SM,
Amirkhani A. (1999) Identification of species and characterization of an outbreak of cutanous leishmaniasis
in a new focus of Iran. Iranian Biomedical Journal, 3:31-39.
35. Ajdary S, Eslami MB, Pakzad S, Alimohammadian MH. (1999) Cytokine production pattern by different
subtypes of T cells in cutaneous leishmaniasis. Iranian Journal of Medical Sciences, 24:1-75.
36. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Labaf Ghassem R, Dowlati Y, Sharifi I,
Aminjavaheri M, Shafiei A, Alimohammadian MH, Hashemi-Fesharaki R, Nasseri K, Godal T, Smith
G, Modabber F. (1998). A randomised, double-blind, controlled trial of a killed L. major vaccine plus
BCG against zoonotic cutaneous leishmaniasis in Iran.Vaccine, 17: 466-472.
37. Malekzadeh Sh., Hosseini SMH, Darabi H and Alimohammadian MH (1998). Partially induced
protection by a fraction of Leishmania major promastigotes against murine leishmaniasis. Iranian
Biomedical Journal, 2: 27-32.
38. Alimohammadian MH, Kojori ZF, Darabi H, Malekzadeh Sh, Yousefbeig M, Irvani-nia F. (1997)
Soluble leishmanin as an ideal reagent for skin testing in human leishmaniasis. Iranian biomedical journal,
1: 39-47.
39. Khabiri AR, Alimohammadian MH, Shokri F. (1997). Preparation of monoclonal antibodies against the
common determinants of HBsAg. Iranian Journal of Medical Sciences, 22: 38-44.
40. Rafati S, Couty-Jouve S, Alimohammadian MH, Louis JA. (1997) Biochmical analysis and
immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clinical and
Experimental Immunology, 110: 203-211.
41. Rafati-Seyedi-Yazdi S, Couty-Jouve S, Alimohammadian MH, Dowlati Y. (1997). Evaluation of cellular
Immune response of recovered human cutaneous leishmaniasis to amastigote soluble Leishmania major
antigens. Medical Journal of Islamic Republic of Iran, 11: 33 - 38.
42. Ajdari S, Hosseini SMH, and Alimohammadian MH, (1997). Recombinant IL-1 promottes leishmaniasis in
the susceptible mice. Microbiology and Immunology, 41: 281-283.
43. Mahmodzadeh Niknam H, Alimohammadian MH, Nasefat S, Amirkhani A. (1996). Effect of mammalian
ambient temperature on Leishmania major promastigotes: viability, morphology and immunogenicity in
BALB/c mice. Iranian Journal of Medical Sciences, 21: 125-129.
44. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamecipour A, Ehsasi S, Hashemi-Fesharaki R,
Ale-Agha S, Modabber F. (1996). Comparative safety and immunogenicity trial of two killed Leishmania
major vaccines with or without BCG in human volunteers. Clinics in Dermatology,14: 489-495.
45. Niknam HM, Mansoori P, nikbin B, Deneshpajouh M, Amirkhani A, and Alimohammadian MH, (1996).
HLA Class I in Iranian psoriatic patients. Medical Journal of Islamic Republic of Iran, 10: 37-41.
46. Alimohammadian MH. (1995). The role of immune cell interctions and cytokine network in immunity
against leishmaniasis. In: Immunology Update. Proceeding of the Third Iranian Congress of Allergy &
immunology, Shiraz University of Medical Sciences,!Iran 1995, Publisher: Iranian Journal of Medical
Sciences, pp. 80-88.
47. Alimohammadian MH, Kivanjah M, Pak F, Gaznavi A, Kharazmi A: (1993). Evaluation of the efficacy of
Iran leishmanin and comparison with leishmanins form Wellcome (UK) and Roma (Italy) in cured
cutaneous leismaniasis patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87:
550-551.
48. Alimohammadian MH, Hakimi H, Nikseresht MH. (1993). The preparation and evaluation of reference
leishmanin from L. major for use in man for diagnostic and experimental purposes. Med J Isla Rep Iran,
7:23-28.
49. Nobakht M, Simforoush N, Alimohammadian MH, Amir Ansari B, (1990). The Role of T lymphocyte
subpopulation in renal allograft rejection. Med J Isla Rep Iran, 4: 47-52.
50. Modabber F, Alimohammadian MH, Khamesipour A, Pourmand M, Kamali M, and Nasseri M. (1980).
Studies on the genetic control of visceral leishmaniasis in BALB/c mice by L. tropica. In: Genetic Control of
Natural Resistance and Malignancy, E Skamene, PAL Konashavens, and M Landy (Eds). pp. 29-37.
51. Alimohammadian MH, and Modabber F. (1979). Preliminary studies of the effect of levamisol on the
immune response of mice infected with Leishmania. Iranian Journal of public Health, 8: 71-85 (Farsi), 118-
119 (English abstract).
Also 10 articles have published in Farsi journals
11. Articles presented in congress:
7

11.1 Alimohammadian MH, Asadpour A, Riazirad F, Khazee V. A Strain of Leishmania major
Induces Expression of Th1 Cytokines mRNA in Lymph Node Cells of BALB/c Mice. IBS
congress, Oral, 14-18 Sep 2010, Rimini, Italy.
11.2 Alimohammadian MH, Riazirad F, Ajdari S, and Noyes H. Interleukin15 gene is
associated with risk of conversion on the leishmanin skin test after exposure to
Leishmania major. World Leish 4, oral, 3-7 February 2009, Lucknow, India.
11.3 Alimohammadian MH, Darabi H, Ajdary S, Khaze V, Riazirad FTorkabadi E. Genetically
different strains of Leishmania major show distinct virulence and imunogenicity in
C57BL/6 mice. J. of Biotechnology, 13 th International Biotechnology Symposium and
Exibition, oral, 12-17 October 2008, Dalian, China.
11.4 Alimohammadian MH, Darabi H, Ajdary S, Khaze V, Riazirad F, Torkabadi E. Selection
of an ideal strain from Leishmania major with high immunogenicity and low
pathogenicity for vaccine studies. 13th International Congress of Immunology, Rio de
Janeiro, Brazil, poster, Aug 21-25, 2007
.
11.5 Alimohammadian MH, Ajdari S, Riaz-rad F, Torkabadi E, Rezaeian A. Genetic
variability of Leishmnia major in different endemic areas of cutaneous
leishmaniasis in Iran. 11 th International Congress of Parasitology, Glasgow,
England, oral, August 2006.
11.6 Alimohammadian M, Lemp SJ, Iraqi FA, Naessens J, Mburu D, Agaba M,
Anderson S, Brass A, and Noyes HA. Identification of gene networks associated
with anaemia caused by Trypanosoma congolense. 11 th International Congress of
Parasitology, Glasgow, England, poster, August 2006.
11.7 Farajnia S, Kariminia A, Khalili G, Babaie H, Alimohammadian MH, Gooya
MM, Oskouei ShA. Cloning, expression and evaluation of recombinant
Leishmania infantum K39 antigen for serodiagnosis of visceral leishmniasis in
endemic region of Iran11 th International Congress of Parasitology, Glasgow,
England, poster, August 2006.
11.8 Alimohammadian MH. Subunit vaccines for leishmaniasis. 8 th Iranian Congress
of Immunology and Allergy. Tehran, oral, may 2006
11.9 Alimohammadian MH. Immunology of cutaneous leishmaniasis. Cutaneous
leishmaniasis Seminar, organized by Center for Research and Training on Skin
Diseases & Leprosy Tehran, oral, 2005.
11.10 Alimohammadian MH. Immunology of parasitic infections. Immunology of
Infectious Diseases congress. Sari, Iran, oral, 2005.
11.11 Alimohammadian MH, Tashakori M, Ajdary S, Kariminia A. Characterization of
Leishmania species and L. major strains in endemic areas of Iran. 10 th Congress of
Parasitology, Vancouver, Canada, oral, 2002.
11.12 Farajnia S, Alimohammadian MH, Karimi M, Barkhordari M, Mahboudi F.
Cloning, sequencing and molecular characterization of P4 homologous gene in L.
major. 3 rd European Congress on Tropical Medicine and International Health.
Lisbon, Portugal. 2002.
11.13 Alimohammadian MH, Khabiri AR, Bagheri F, Kariminia A. Isolation of a
Leishmania major protein capable of inducing delayed-type hypersensitivity
8

eaction and Th1 response. 6 th Iranian Congress of Immunology and Allergy.
Tehran, oral, 2002.
11.14 Alimohammadian MH, Malekzadeh S, Kariminia A, Darabi H. Procyclic
promastigotes of L. major confer more efficient immunity than metacyclic one in
BALB/c mice. Worldleish 2 Congress, Crete, Greece, poster, 2001.
11.15 Alimohammadian MH, Khamesipour A, Sacks D, Darabi H, Firooz A,
Malekzadeh Sh, Dowlati Y, Modabbee F. The role of BCG in immune
responses induced by multiple doses of autoclaved Leishmania major vaccine
injection. 2th Worldleish Congress, Crete, Greec, poster, 2001.
11.16 Alimohammadian MH, Darabi H, Malekzadeh Sh, Mahmoudzadeh-Niknam
H, Ajdary S, Bahonar A, Moffarah A. Cross-reactive responses to Leishmania
major antigen in healthy volunteers vaccinated with BCG. XVth International
Congress for Tropical Medicine and Malaria. Cartagena, Colombia, oral, 2000.
11.17 Alimohammadian MH, Khamesipour A, Sacks D, Darabi H, Firooz A,
Malekzadeh S, Bahonar A, Dowlati Y. Immune responses of healthy volunteers to
multiple injections of an autoclaved Leishmania major vaccine plus BCG. 2
FIMSA congress Immunology and allergology in the Asia-Oceania Bancoque,
Thailand, poster 2000.
11.18 Alimohammadian MH. Preparation and evaluation of standard leishmanin. 3th
Meeting of Vaccine Development Team. Organized by TDR, WHO. Isfahan, oral,
2000.
11.19 Alimohammadian MH, Darabi H, Kariminia A, Ajdary S, and Modabber F.
Induction of Th1 response by Leishmania major promastigotes when used as
adjuvant. 10th International Congress of Immunology, New Delhi, poster 1998.
11.20 Rafati S, Abrambaba A, Bakhshayesh M, Vafa M, Alimohammadian MH.
Vaccination of Balb/c mice with 24 Kda antigen of amastigote of leishmania
major. 10 th International Congress of Immunology New Delhi, 1998.
11.21 Khabiri AR, Hoseini SMH, Bageri F, Jalili A, Malekzadeh S, and
Alimohammadian MH. Preparation and partial characterization of specific
monoclonal antibodies against PSA-2 of L .major. 10 th International Congress of
Immunology New Delhi, 1998.
11.22 Alimohammadian MH, Darabi H, Malekzadeh Sh, Aslanian S. T-cell phenotypes
and cytokine profiles in cases cured and patients with active Leishmania major
infection. Scientific Meeting of International Institute Pasteurs of the World.
Paris, oral. 1997.
11.23 Alimohammadian MH, Darabi H, Aslanian S., Expansion of specific CD4+ T-
cells, producing IFN- by stimulated PBMCs of cured and patients with
Leishmania major infection. First World Congress on Leishmaniosis. Istanbul,
Turkey, oral, 1997.
11.24 Alimohammadian MH, Yousefbeig M, Darabi H, Irvaninia F. Selection of a
reference leishmanin for skin testing in human leishmaniasis. 14th international
Congress for Tropical Medicine and Malaria. Nagasaki, Japan, oral, 1996.
11.25 Alimohammadian MH. The preparation and evaluation of a standard leishmanin
and production of an autoclaved vaccine. Workshop: Development of protocols
for Vaccine Efficacy Trials Against Leishmaniases, Dizin, Iran, organized by
TDR, WHO, oral, 1993.
11.26 Alimohammadian MH. Rivier D, Bovay Ph, Mauel J, Kemp M, Kharazmi A.
Potential adjuvant effect of L. major on the cellular and humoral immune
9

esponses. 8th International Congress of immunology, Budapest, Hungary. Poster,
1992.
12. Test and Techniques:
12.1. ELISA for detection of leishmanial antigen.
12.2. T cell proliferation assay.
12.3. Cell culture and hybridoma technique for production of monoclonal antibodies.
12.4. Cytokine assay in supernatant of lymphocyte culture.
12.5. Phenotyping analysis by flow cytometer
12.6. Assessment of intracellular cytokines by flow cytometer.
12.7. Identification of Leishmania species by IF and ELISA using specific monoclonal
antibodies.
12.8 Identification of Leishmania species by isoenzyme analysis.
12.9. Identification of Leishmania species by molecular techniques: kDNA-PCR,
RAPD, RFLP and SSCP (ITS1 and ITS2).
12.10. Characterization of Leishmania species by cloning and sequencing method.
12.11. Quantitation of DNA and cDNA by Quantitative-PCR (Realtime-PCR).
12.12. Comparison of genes expression by relative quantitation.
13. Professional membership:
Member of Editorial Board, Iranian Biomedical Journal, 1997-2008.
Member of Editorial Board, Iranian Journal of Immunology, 2004-2008.
Member of Iranian Society of Immunology & Allergy (ISIA), 2005-2008.
14. Position Held:
Head, Department of Immunology, Pasteur Institue of Iran, 1985 –2001, 2003- present.
- Director of Diagnostic Laboratory Affairs, Minstry of Health, Theatment and
Education, 1994- 1995.
- WHO consultant: assignment for " Leishmaniasis Vaccine Production in Pakistan”,
December 1994-January 1995
- Director of research, Pasteur Institute of Iran, 1992-1993.
- Director of research and education, Iranian Blood Transfusion Services, Tehran, 1987-
1990.
- Production manager, Pharmaceutical group, National Iranian Industries Organization
(NIIO), 1981-1984.
15. Professional Experience:
Cell culture end hybridoma technology.
Evaluation of candidate vaccine for leishmaniasis.
Identification of species and sub-species of Leishmania.
Detection of DNA in infectious samples by PCR and Realtime PCR.
Expression of genes by Real-time PCR.
16. Invention & Patent:
10

In Iran: Preparation of Leishmanin reagent
In NCBI, NIH: Eight new genes for Leishmania spcies by following accession number:
AY079097: Leishmania major class I nuclease gene
AY487805: Leishmania donovani, class I nuclease mRNA
AY283793: Leishmania major strain MHOM/Ir/02/PIIDT1
AY260965: Leishmania major strain MHOM/Ir/02/PIICC1
AY550178: Leishmania major strain MHOM/Ir/00/PII1
AY573187: Leishmania major strain MHOM/Ir/00/PII2
11